Fate Therapeutics director granted 175,800 stock options

Fate Therapeutics director Laura Hamill received a grant of stock options to acquire 175,800 shares of Common Stock.

Rhea-AI Filing Summary

Fate Therapeutics director Laura Hamill received a grant of stock options to acquire 175,800 shares of Common Stock. The options have an exercise price of $2.06 per share and expire on June 12, 2036. This grant was made under the company’s Amended and Restated Non-Employee Director Compensation Policy, which provides equity upon a director’s appointment or election. The options vest in 36 equal monthly installments starting on June 12, 2026 and will be fully vested on June 12, 2029, contingent on Hamill’s continued service on the Board.

Insider Trade Summary

Grant/Award: 175,800 shares

Grant/Award 1 txn

Insider Hamill Laura

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	175,800	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 175,800 contracts (Direct)

Footnotes (2)

1. F1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for an equity grant upon a director's appointment or election to the Board of Directors.
2. F2. The shares subject to this option shall vest in 36 equal monthly installments following June 12, 2026, such that all of the shares shall be fully vested and exercisable on June 12, 2029, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.

Key Figures

Option grant size: 175,800 options Exercise price: $2.06 per share Expiration date: June 12, 2036 +3 more

6 metrics

Option grant size 175,800 options Stock Option (Right to Buy) granted to director Laura Hamill

Exercise price $2.06 per share Conversion or exercise price of the stock options

Expiration date June 12, 2036 Option term end date for the grant

Underlying shares 175,800 shares Common Stock underlying the stock options

Post-grant derivative holdings 175,800 options Total options directly held after the transaction

Vesting period 36 monthly installments Vesting from June 12, 2026 to June 12, 2029

Key Terms

Stock Option (Right to Buy), Amended and Restated Non-Employee Director Compensation Policy, Common Stock, vest in 36 equal monthly installments

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Amended and Restated Non-Employee Director Compensation Policy financial

"provides for an equity grant upon a director's appointment or election"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vest in 36 equal monthly installments financial

"The shares subject to this option shall vest in 36 equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Fate Therapeutics (FATE) director Laura Hamill report on this Form 4?

Laura Hamill reported receiving a grant of stock options for 175,800 shares of Fate Therapeutics Common Stock. These options are part of the company’s non-employee director compensation program and represent equity-based compensation rather than an open-market purchase or sale.

What are the key terms of Laura Hamill’s Fate Therapeutics (FATE) stock option grant?

The grant covers 175,800 options with an exercise price of $2.06 per share and an expiration date of June 12, 2036. All options relate to Fate Therapeutics Common Stock and were granted as non-employee director compensation.

How and when do Laura Hamill’s Fate Therapeutics (FATE) options vest?

The options vest in 36 equal monthly installments starting after June 12, 2026. They will be fully vested and exercisable by June 12, 2029, provided Laura Hamill continues to serve the company as a director on each vesting date.

Is Laura Hamill’s Fate Therapeutics (FATE) Form 4 transaction a market purchase or sale?

No, the Form 4 reflects a grant of stock options as compensation, not a market trade. The options were awarded under Fate Therapeutics’ Amended and Restated Non-Employee Director Compensation Policy upon her appointment or election to the Board.

How many Fate Therapeutics (FATE) options does Laura Hamill hold after this grant?

After this grant, Laura Hamill directly holds 175,800 stock options for Fate Therapeutics Common Stock. These options are subject to future vesting over 36 months and an exercise price of $2.06 per share, with expiration in June 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hamill Laura

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CALIFORNIA 92131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.06	06/12/2026		A(1)		175,800		(2)	06/12/2036	Common Stock	175,800	$0	175,800	D

Explanation of Responses:

1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for an equity grant upon a director's appointment or election to the Board of Directors.

2. The shares subject to this option shall vest in 36 equal monthly installments following June 12, 2026, such that all of the shares shall be fully vested and exercisable on June 12, 2029, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.

	/s/ Cindy Tahl, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)